Shots:
- The company has initiated a P-I open-label study to evaluate the safety, tolerability, PK & preliminary efficacy of HMPL-295 & to determine MTD and RP2D in patients with advanced malignant solid tumors. The 1st patient has been dosed on 02 Jul, 2021
- Following the initial dose-escalation stage, 10 to 15 patients will enroll at RP2D to assess the safety & preliminary efficacy of HMPL-295. Currently, the company retain all rights to HMPL-295 globally
- HMPL-295 is a highly selective ERK inhibitor addressing the RAS-MAPK pathway & has the potential to address intrinsic or acquired resistance from upstream mechanisms. The company plans an exploratory study of HMPL-295 on PK biomarkers
Click here to read full press release/ article | Ref: PR Newswire | Image: Yahoo Finance
The post Hutchmed Initiates P-I Trial of HMPL 295 for the Treatment of Advanced Solid Tumors in China first appeared on PharmaShots.
